Science review: Natriuretic peptides in critical illness

The present review will cover the mechanisms of release and the potential pathophysiological role of different natriuretic peptides in critically ill patients. By focusing on the cardiovascular system, possible implications of natriuretic peptides for diagnosis and treatment will be presented. In critical illness such as sepsis, trauma or major surgery, systemic hypotension and an intrinsic myocardial dysfunction occur. Impairment of the cardiovascular system contributes to poor prognosis in severe human sepsis. Natriuretic peptides have emerged as valuable marker substances to detect left ventricular dysfunction in congestive heart failure of different origins. Increased plasma levels of circulating natriuretic peptides, atrial natriuretic peptide, N-terminal pro-atrial natriuretic peptide, brain natriuretic peptide and its N-terminal moiety N-terminal pro-brain natriuretic peptide have also been found in critically ill patients. All of these peptides have been reported to reflect left ventricular dysfunction in these patients. The increased wall stress of the cardiac atria and ventricles is followed by the release of these natriuretic peptides. Furthermore, the release of atrial natriuretic peptide and brain natriuretic peptide might be triggered by members of the IL-6-related family and endotoxin in the critically ill. Apart from the vasoactive actions of circulating natriuretic peptides and their broad effects on the renal system, anti-ischemic properties and immunological functions have been reported for atrial natriuretic peptide. The early onset and rapid reversibility of left ventricular impairment in patients with good prognosis associated with a remarkably augmented plasma concentration of circulating natriuretic peptides suggest a possible role of these hormones in the monitoring of therapy success and the estimation of prognosis in the critically ill.

• Publication year

  2004

• Venue

  Critical Care

• Publication date

  2004-06-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/cc2890PMID 15469596PMCID 1065010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis

  2004cited by this paper
• N‐terminal probrain natriuretic peptide (NT‐proBNP) in the emergency diagnosis and in‐hospital monitoring of patients with dyspnoea and ventricular dysfunction

  2004cited by this paper
• The natriuretic peptides

  2004cited by this paper
• 1049-105 Increased levels of Nt-ProANP and Nt-ProBrain natriuretic peptide as markers of cardiac depression in septic patiens

  2004cited by this paper
• N‐terminal pro‐brain natriuretic peptide for discriminating between cardiac and non‐cardiac dyspnoea

  2004cited by this paper
• Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction

  2003cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis

  2003cited by this paper
• Cardiac natriuretic peptides:a proteomic window to cardiac function and clinical management.

  2003cited by this paper
• Opportunities for improvement in the diagnosis and treatment of heart failure

  2003cited by this paper
• Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function.

  2003cited by this paper
• What causes elevated B-type natriuretic peptide in patients without heart failure?

  2003cited by this paper
• B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction

  2003cited by this paper
• N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure.

  2003cited by this paper
• Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.

  2002cited by this paper
• Inhibition of cyclooxygenase-2 by natriuretic peptides.

  2002cited by this paper
• Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recordings

  2002cited by this paper
• Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea.

  2002cited by this paper
• The Atrial Natriuretic Peptide as a Regular of Kupffer Cell Functions

  2002cited by this paper
• Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

  2002cited by this paper
• Prevention of Ischemia-Reperfusion Injury in the Rat Liver by Atrial Natriuretic Peptide

  2002cited by this paper
• Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes.

  2002cited by this paper
• N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes

  2002cited by this paper
• Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs.

  2001cited by this paper
• Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.

  2001cited by this paper
• The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

  2001cited by this paper
• A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

  2001cited by this paper
• alpha-atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock.

  2001cited by this paper
• Differential Secretion of Atrial and Brain Natriuretic Peptide in Critically Ill Patients

  2001cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper
• Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: Incidence, clinical implications, and prognosis

  2001cited by this paper
• Pro-atrial natriuretic peptide hormone from right atria is correlated with cardiac depression in septic patients

  2001cited by this paper
• Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina

  2000cited by this paper
• a-Atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock

  2000cited by this paper
• cGMP-Mediated Inhibition of TNF-α Production by the Atrial Natriuretic Peptide in Murine Macrophages1

  2000cited by this paper
• A rapid bedside test for B‐type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure

  2000cited by this paper
• AGE-SPECIFIC INCIDENCE AND OUTCOME OF SEPSIS IN THE US

  1999cited by this paper
• An immunoluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure.

  1999cited by this paper
• Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro.

  1999cited by this paper
• Treating patients with severe sepsis.

  1999cited by this paper
• Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort.

  1999cited by this paper
• Myocardial dysfunction in sepsis: mechanisms and therapeutic implications.

  1999cited by this paper
• Circulating endothelin and nitrate-nitrite relate to hemodynamic and metabolic variables in human septic shock.

  1999cited by this paper
• Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure.

  1999cited by this paper
• Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.

  1999cited by this paper
• Treating patients with severe sepsis.

  1999cited by this paper
• Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes.

  1999cited by this paper
• Autocrine Regulation of Inducible Nitric-oxide Synthase in Macrophages by Atrial Natriuretic Peptide*

  1998cited by this paper
• Natriuretic peptides.

  1998cited by this paper
• Lipopolysaccharide and Its Analog Antagonists Display Differential Serum Factor Dependencies for Induction of Cytokine Genes in Murine Macrophages

  1998cited by this paper
• Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.

  1998cited by this paper
• A Novel Cardiac Hormone Related to A-, B-, and C-Type Natriuretic Peptides.

  1998cited by this paper
• A novel cardiac hormone related to A-, B- and C-type natriuretic peptides.

  1998cited by this paper
• Relation between chubby cheeks and visceral fat.

  1998cited by this paper
• Endotoxins as Potential Mediators of Myocardial Depression

  1997cited by this paper
• Mechanisms of mechanical load-induced atrial natriuretic peptide secretion: role of endothelin, nitric oxide, and angiotensin II

  1997cited by this paper
• Sepsis alters myocardial and plasma concentrations of endothelin and nitric oxide in rats.

  1997cited by this paper
• The atrial natriuretic peptide receptor antagonist HS 142-1 improves cardiovascular filling and mean arterial pressure in a hyperdynamic ovine model of sepsis.

  1997cited by this paper
• Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury.

  1997cited by this paper
• Lipopolysaccharide depresses cardiac contractility and beta-adrenergic contractile response by decreasing myofilament response to Ca2+ in cardiac myocytes.

  1997cited by this paper
• Left ventricular systolic and diastolic function in septic shock

  1997cited by this paper
• Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction.

  1997cited by this paper
• Elevated soluble CD14 receptors and altered cytokines in chronic heart failure.

  1997cited by this paper
• Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.

  1997cited by this paper
• Effects of atrial natriuretic peptide on phagocytosis and respiratory burst in murine macrophages.

  1997cited by this paper
• Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators.

  1997cited by this paper
• Circulating interleukin-6 in severe heart failure.

  1997cited by this paper
• Sir Isaac Newton, sepsis, SIRS, and CARS.

  1996cited by this paper
• Natriuretic peptide receptors in human artery and vein and rabbit vein graft.

  1996cited by this paper
• Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.

  1996cited by this paper
• Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular natriuretic peptide system in vascular growth inhibition.

  1996cited by this paper
• Role of atrial natriuretic factor in volume control.

  1996cited by this paper
• C-type natriuretic peptide in human coronary atherosclerotic lesions.

  1996cited by this paper
• Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction.

  1996cited by this paper
• C-type natriuretic peptide.

  1996cited by this paper
• Natriuretic peptide receptors on rat thymocytes: inhibition of proliferation by atrial natriuretic peptide.

  1996cited by this paper
• Response of human artery, vein, and cultured smooth muscle cells to atrial and C-type natriuretic peptides.

  1996cited by this paper
• The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study.

  1995cited by this paper
• Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II.

  1995cited by this paper
• The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma.

  1995cited by this paper
• Round table conference on clinical trials for the treatment of sepsis.

  1995cited by this paper
• Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes.

  1995cited by this paper
• Expression and differential regulation of natriuretic peptides in mouse macrophages.

  1995cited by this paper
• Roundtable Conference on Clinical Trials for the Treatment of Sepsis. Brussels, March 12-14, 1994.

  1995cited by this paper
• Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.

  1995cited by this paper
• Prevention of ischemia/reperfusion injury in the rat liver by atrial natriuretic peptide.

  1994cited by this paper
• Three Peptides From the Atrial Natriuretic Factor Prohormone Amino Terminus Lower Blood Pressure and Produce Diuresis, Natriuresis, and/or Kaliuresis in Humans

  1994cited by this paper
• N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.

  1994cited by this paper
• Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients.

  1994influential reference
• Complement and tumor necrosis factor‐α contribute to Mac‐1 (CD11b/CD18) up‐regulation and systemic neutrophil activation during endotoxemia in vivo

  1994cited by this paper
• Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.

  1994cited by this paper
• Skeletal muscle partial pressure of oxygen in patients with sepsis

  1994cited by this paper
• Peak systolic pressure/end‐systolic volume ratio, a load‐independent measure of ventricular function, is reversibly decreased in human septic shock

  1994cited by this paper
• Effect of acute lung injury and coexisting disorders on plasma concentrations of atrial natriuretic peptide

  1994cited by this paper
• Endothelin-1 and atrial natriuretic peptide in septic shock.

  1993cited by this paper
• Pathogenetic mechanisms of septic shock.

  1993cited by this paper
• Guidelines for the Use of Innovative Therapies in Sepsis

  1993cited by this paper
• Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.

  1993cited by this paper
• Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction.

  1993cited by this paper
• C-type natriuretic peptide inhibits intimal thickening after vascular injury.

  1993cited by this paper
• Receptors of atrial natriuretic factor.

  1992cited by this paper

• Predictive Value of Blood N-Terminal Pro-Brain Natriuretic Peptide Concentrations for Early Patent Ductus Closure in Very Preterm Infants

  2021cites this paper
• Serum brain natriuretic peptide in healthy Nigerian newborn babies

  2021cites this paper
• N-terminal pro brain natriuretic peptide as a marker of myocardial dysfunction in newborns with perinatal asphyxia

  2020cites this paper
• Prognostic Value of N-terminal Probrain Natriuretic Peptide for Patients with Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis

  2020cites this paper
• The Challenge of Perioperative Fluid Management in Elderly Patients

  2019cites this paper
• The Influence of Perioperative Fluid Therapy on N-terminal-pro-brain Natriuretic Peptide and the Association With Heart and Lung Complications in Patients Undergoing Colorectal Surgery

  2019cites this paper
• Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients

  2019cites this paper
• Early NT-proBNP levels as a screening tool for the detection of hemodynamically significant patent ductus arteriosus during the first week of life in very low birth weight infants

  2018cites this paper
• N Terminal Pro B Type Natriuretic Peptide as a Tool to Diagnose Hemodynamically Significant Patent Ductus Arteriosus in Older Infants

  2018cites this paper
• Pilot Trial Evaluating Mid-Regional Pro-Atrial Natriuretic Peptide as a Marker of Sepsis after Abdominal Surgery

  2018cites this paper
• Diagnostic accuracy of plasma atrial natriuretic peptide concentrations in cats with and without cardiomyopathies.

  2018cites this paper
• Cardiac biomarkers in neonatology: BNP/NTproBNP, troponin I/T, CK-MB and myoglobin – a systematic review

  2017cites this paper
• orrelation of inflammatory and cardiovascular biomarkers with pneumonia everity scores

  2017cites this paper
• N-terminal pro-brain natriuretic peptide measurements in hemodynamically significant patent ductus arteriosus in preterm infants

  2016cites this paper
• Umbilical arterial N-terminal pro-B-type natriuretic peptide levels in preeclampsia, fetal growth restriction, preterm birth and fetal distress.

  2016cites this paper
• A review on B-type natriuretic peptide monitoring: assays and biosensors

  2016cites this paper
• Ideal target arterial pressure after control of bleeding in a rabbit model of severe traumatic hemorrhagic shock: results from volume loading-based fluid resuscitation.

  2015cites this paper
• Timing of Dynamic NT-proBNP and hs-cTnT Response to Exercise Challenge in Asymptomatic Children with Moderate Aortic Valve Regurgitation or Moderate Aortic Valve Stenosis

  2015cites this paper
• Disfunción moicárdica en la sepsis: utilidad de la ecocardiografía y los biomarcadores

  2015influential citation
• Correlation of inflammatory and cardiovascular biomarkers with pneumonia severity scores.

  2014cites this paper
• Serial N-terminal pro-brain natriuretic peptide measurement as a predictor of significant patent ductus arteriosus in preterm infants beyond the first week of life

  2014cites this paper
• Role of N-terminal pro B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease

  2014cites this paper
• Study the Effect of Hyperthyroidism on Heart Function by Using BNP as Indicator

  2014cites this paper
• Scorpion venoms, kidney and potassium.

  2013cites this paper
• B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants

  2013cites this paper
• C-type natriuretic peptide: a new cardiac mediator.

  2013cites this paper
• Clinical Applications of Plasma B-type Natriuretic Peptide Assays in Preterm Infants with Patent Ductus Arteriosus

  2013cites this paper
• Obstructive sleep apnea and heart disease: the biomarkers point of view.

  2013cites this paper
• Changes in serum levels of BNP ( B-type natriuretic polypeptide ) associated with chronic obstructive pulmonary disease exacerbations

  2013cites this paper
• Biomarkers in community-acquired pneumonia: A state-of-the-art review

  2012cites this paper
• Can a clinical decision rule help ductus arteriosus management in preterm neonates?

  2012cites this paper
• The relation between brain natriuretıc peptide and patent ductus arteriosus in premature infants

  2012cites this paper
• Cardiac biomarkers in neonatal hypoxic ischaemia

  2012cites this paper
• Plasma renin concentration as a predictor of outcome in a medical intensive care setting: a retrospective pilot study.

  2012cites this paper
• Optimisation of Fluid Therapy in Colorectal Surgery

  2011influential citation
• Therapeutic changes of plasma N-terminal pro-brain natriuretic peptide concentrations in 9 dogs with patent ductus arteriosus.

  2011cites this paper
• Natriuretic peptides: Diagnostic and therapeutic use

  2011cites this paper
• Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus.

  2011cites this paper
• Hypernatremia without water depletion.

  2011cites this paper
• Biomarqueurs des états septiques sévères : vers de nouvelles stratégies thérapeutiques individualisées

  2011cites this paper
• Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD.

  2011cites this paper
• The role of endothelium and endogenous vasoactive substances in sepsis.

  2010cites this paper
• Biomarkers of corticosteroid-induced hypertrophic cardiomyopathy in preterm babies.

  2010cites this paper
• Water, taken in moderation, cannot hurt anybody (Mark Twain 1835–1910)

  2010influential citation
• The Use of N-Terminal-Pro-BNP in Preterm Infants

  2009cites this paper
• Natriuretic peptides in septic patients.

  2009cites this paper
• Measurement of N-terminal proatrial natriuretic peptide in plasma of cats with and without cardiomyopathy.

  2009cites this paper
• N-terminal proB-type natriuretic peptide : a measure of significant patent ductus arteriosus

  2008cites this paper
• Natriuretic peptides in cardiovascular diseases

  2008cites this paper
• Plasma aldosterone, vasopressin and atrial natriuretic peptide in hypovolaemia: a preliminary comparative study of neonatal and mature horses.

  2008cites this paper
• NT-proBNP is not elevated in patients with obstructive sleep apnoea.

  2008cites this paper
• Hyponatremia and Comparison of NT-pro-BNP Concentrations in Blood Samples from Jugular Bulb and Arterial Sites after Traumatic Brain Injury in Adults: A Pilot Study

  2007cites this paper
• Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?

  2007cites this paper
• B-Type Natriuretic Peptide and Sepsis: It Is Not Just the Heart

  2007cites this paper
• Brain natriuretic peptide increases in septic patients without severe sepsis or shock.

  2007cites this paper
• Pro-Atrial Natriuretic Peptide (proANP) A New Prognostic Marker in Clinical Outcome of Critically Ill Patients

  2007cites this paper
• Mechanisms of pathogenesis in Chagas disease

  2007cites this paper
• N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus

  2007cites this paper
• Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis.

  2006cites this paper
• Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides.

  2006cites this paper
• Circulating levels of pro‐atrial natriuretic peptide in lower respiratory tract infections

  2006cites this paper
• Endocrine markers of severity and prognosis in critical illness.

  2006influential citation
• Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study

  2004cites this paper